GreenLight Clinical team is established and run by a group of highly-regarded physicians and researchers with a multi-disciplinary skill set, and a proven track record in delivering high quality research output to our clients.

Our staff of experienced, knowledgeable clinical trial professionals aims to provide the highest quality research outcomes for our partners, and as a full-service provider, our teams cover all aspects of clinical trial management, drug & device development and global regulatory affairs.



Dr. Sasi Suda – MD, PhD (USyd)

Dr. Suda is qualified as a medical practitioner in Australia and has extensive experience in the pharmaceutical industry and clinical research as both a researcher and clinical trial professional.
Over the past 15 years, Dr. Suda has served variously as a clinical research specialist in diverse areas including regulatory affairs, protocol development and compliance, site management, clinical operations, and drug safety and pharmacovigilance.

This combined clinical experience and research training has been applied across multiple positions in the pharmaceutical, biotechnology and medical industries in Australia, and Dr. Suda has held key executive and clinical management roles at Alcon Laboratories, Novo Nordisk Pharmaceuticals and Avexa Australia.


Clinical Associate Professor

Andrew Chang – MBBS(Hons), PhD (USyd), FRANZCO, FRACS

Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. He holds an academic appointment of Clinical Associate Professor at the University of Sydney.

He is Consultant Vitreoretinal Surgeon and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.
He graduated from University of Sydney Medical School, underwent ophthalmology training at the Sydney Eye Hospital and fellowship training at Royal Victorian Eye and Ear Hospital and in the United States. He was awarded a PhD for research into retinal and choroidal angiography performed in the Universities of California and Sydney.
His commitment to international ophthalmology includes Secretary General of the Asia-Pacific Vitreoretinal Society (APVRS). He is a clinician advisor to the Department of Health Australia. He is a Director of the RANZCO Board and the Sydney Eye Hospital Foundation Board. Professional awards include the Achievement Award and Distinguished Service Award of the Asia Pacific Academy of Ophthalmology (APAO) and the RANZCO Excellence in Teaching Award.
Associate Professor Chang is enthusiastically involved in basic science and clinical trials research receiving research grant funding in Australia and USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals including Clinical and Experimental Ophthalmology.
In wider healthcare activities, Associate Professor Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drug and devices by engaging in clinical trials development. He is driving strategies aimed at better patient engagement with healthcare professionals using the latest in cloud, IoT and Artificial Intelligence.


Chief Financial Officer – Mark Summerville

Mark Summerville has over 22 years experience in the healthcare market in both Chief Financial Officer and General Management roles.

He has extensive experience in the Australian healthcare market, and spent over 10 years working in the Asia Pacific region, having lived in China, Hong Kong and Belgium during this time. Mark led business transformations as well as mergers and acquisitions building finance and operations capability and governance structures that resulted in sustainable long term profitable growth outcomes.

Mark has a Bachelor of Business (Accountancy) Degree from Charles Sturt University, and is a Certified Practicing Accountant (CPA). He is also a Member of the Australian Institute of Company Directors.

Global People and Culture Director – Tracy Mellor

Tracy has over 20 years experience in the Pharmaceutical industry in Business Development in BMS, Kabi Pharmacia Farmitalia Upjohn and in Training, Leadership Development and People and Culture for Novo Nordisk in Europe and Australia.

She has proven successful Business Leadership experience in several global roles and understands the challenges and benefits of working in Australia for a global company.

Tracy believes in life-long learning – she’s a Chartered Fellow of the Chartered Institute of Personnel and Development (FCIPD) a Fellow of the Australian Human Resources Institute (FAHRI), a Fellow of the Australian Institute of Management (FAIM) and a Graduate of the Australian Institute of Company Directors (GAICD) She was AIM Leader of the Year for NSW.

Her focus is ensuring we employ the best people here at GreenLight Clinical and helping make it a fabulous place to work!

Group General Counsel, Compliance & Risk – Franz D’Lima

Franz D’Lima has over 20 years experience as a senior corporate lawyer and general counsel in global FMCG, healthcare and B2B industries. His diverse experience in ANZ, EMEA, and APAC (including emerging markets such as China and India), has helped him develop an acute understanding of the legal environment in multiple jurisdictions as well as an appreciation of cross-cultural sensitivities.

Franz approaches legal issues from a commercial perspective and has acquired a reputation as a trusted business partner. He has managed a number of complex projects including the successful transition of a US$100M healthcare business in Japan, the divestment of multi-million dollar cigarette paper businesses in Indonesia and the Philippines and established manufacturing facilities and R&D centres across the Asia Pacific region.

Franz has successfully led and defended multifaceted legal actions against government and quasi-government agencies most notably in China, Korea, the Philippines and Thailand.

Franz is a qualified lawyer in both England & Wales, and New South Wales, Australia and specializes in M&A, divestments, strategic alliances, intellectual property, data privacy, anti-bribery, risk and compliance management.

Quality Assurance, Regulatory Affairs and Pharmacovigilance Director – Peter Yeates

Peter has worked with biologicals, medicines, medical devices and health practitioners in the research setting, hospitals and industry for over 35 years and has developed a strong understanding of the product development continuum including reimbursement and post-marketing requirements.

Previous management and director roles in the medical industry (Alcon, AstraZeneca, Pfizer, Janssen Cilag and Wyeth) included Compliance, Medical affairs, Medical information, Medical safety, Regulatory affairs, Reimbursement and Quality. Peter has a reputation for successfully managing difficult projects.

Following graduation from University he was employed as a hospital radiochemist being responsible for the manufacture and diagnostic use of radiopharmaceuticals and completed research in the radiolabelling of monoclonal antibodies for tumour diagnosis at the Garvan Institute of Medical Research and was awarded a Master of Pharmacy.  He later moved to Royal Prince Alfred Hospital and was responsible for the manufacture of radiopharmaceuticals for positron emission tomography (PET) using the ANSTO medical cyclotron in accordance to GMP requirements.

Peter has a Bachelor of Pharmacy (University of Sydney), Master of Pharmacy (University of Sydney) and a Masters of Drug Development Science (University of NSW) and has previously been a University lecturer on Radiopharmacy and Regulatory affairs.


Michael P. Mader
Michael P. Mader
Head of Clinical Operations USA and Europe
Meidong Zhu
Meidong Zhu
Senior Medical Advisor
Poonam Kamboj
Poonam Kamboj
Head of Pharmacovigilance & Drug Safety
Christopher Pardy
Christopher Pardy
Head of Biostatistics
Mark Taylor
Mark Taylor
Head of Regulatory Affairs
Sasa Popovic
Sasa Popovic
Head of Data Management